Market Overview

Sagent Pharma Launches Nafcillin for Injection, USP

Share:
Related SGNT
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3
5 Healthcare Stocks With The Highest EPS Growth Forecast For Next 5 Years
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX (Seeking Alpha)

Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) today announced the launch of Nafcillin for Injection, USP, in two vial presentations and one pharmacy bulk package bottle; all three are latex-free and preservative-free. According to IMS, for the 12 months ending September 2012, the US market for Nafcillin approximated $62 million. As with all products in Sagent's portfolio, Nafcillin features the Company's PreventIV Measures^SM packaging and labeling, designed to help reduce medication errors.

Posted-In: News

 

Related Articles (SGNT)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional